Procalcitonin in Hepatocellular Carcinoma

Completed

• Conditions: Hepatocellular Carcinoma

• Registration Number: NCT01518829
• Lead Sponsor: Ain Shams University

Brief Summary

the value of serum procalcitonin in differentiation between bacterial infection and non infectious inflammation in febrile HCC patients following locoeregional treatment for HCC.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2012-01-24
• Study First Submitted QC: 2012-01-24
• Study First Posted: 2012-01-26
• Study Start: 2012-04
• Primary Completion: 2012-12
• Study Completion: 2013-01
• Status Verified: 2013-09
• Last Update Submitted: 2013-09-29
• Last Update Posted: 2013-10-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1. • Hepatocellular carcinoma patients who will undergo TACE and/or radio-frequency.
2. • Fever more than 38C after 48 hours post intervention.

Exclusion Criteria

1. HCC Patients who does not develop fever after intervention.
2. Proven infection elsewhere (e.g. UTI, chest infection..)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Differantiate between post- embolization syndrom and sepsis following locoregional treatment for hepatocellular carcinoma	6months

Trial Locations

Locations (1)

Tropical medicine department and hepatocellular carcinoma clinic; 🇪🇬 Cairo, Egypt